ArticleBlood2021

Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.

Qingxiao Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.